Sam Watson’s journal round-up for 26th March 2016

Every Monday our authors provide a round-up of some of the most recently published peer reviewed articles from the field. We don’t cover everything, or even what’s most important – just a few papers that have interested the author. Visit our Resources page for links to more journals or follow the HealthEconBot. If you’d like to write one of our weekly journal round-ups, get in touch.

Affordability and availability of off-patent drugs in the United States—the case for importing from abroad: observational study. BMJ [PubMedPublished 19th March 2018

Martin Shkreli has been frequently called “the most hated man in America“. Aside from defrauding investors and being the envied owner of a one-of-a-kind Wu-Tang Clan album, the company of which he was chief executive, Turing Pharmaceuticals, purchased the sole US approved manufacturer of a toxoplasmosis treatment, pyrimethamine, and hiked its price from $13 to $750 per tablet. Price gouging is nothing new in the pharmaceutical sector. An episode of the recent Netflix documentary series Dirty Money covers the story of Valeant Pharmaceuticals whose entire business was structured around the purchase of drug companies, laying off any research staff, and then hiking the price as high as the market could bear (even if this included running their own pharmacies to buy products at these inflated prices). The structure of the US drug market often allows the formation of monopolies on off-patent, or generic, medication, since the process for regulatory approval for a new manufacturer can be long and expensive. There have been proposals though that this could be ameliorated by allowing manufacturers approved by other trusted agencies (such as the European Medicines Agencies) to sell generics in the US while the FDA approvals process takes place. The aim of this paper is to determine how many more manufacturers this would allow into the US drugs market. The authors identify all the off-patent drugs that have been approved by the FDA since 1939 and all the manufacturers of those drugs that were approved by the FDA and by other trusted agencies. No analysis is given of how this might affect drug prices, though there is a pretty obvious correlation between the number of manufacturers and drug prices shown elsewhere. The results show that the proposed policy would increase the number of manufacturers for a sizeable proportion of generics: for example, 39% of generic medications could reach four or more manufacturers when including those approved by non-FDA bodies.

Why internists might want single-payer health care. Annals of Internal Medicine [PubMedPublished 20th March 2018

The US healthcare system has long been an object of fascination for many health economists. It spends far more than any other nation on healthcare (approximately $9,000 per capita compared to, say, $4,000 for the UK) and yet population health ranks alongside middle-income countries like Cuba and Ecuador. Garber and Skinner wondered whether it was uniquely inefficient and identified or questioned a number of issues that may or may not explain the efficiency or lack thereof. One of these was the administrative burden of multiple insurance companies, which evidence suggests does not actually account for much of the total expenditure on health care. However, Garber and Skinner say this does not take into account time spent by clinical and non-clinical staff on administration within hospitals. In this opinion piece, Paul Sorum argues that internists should support a move to a single-payer system in the US. One of his four points is the administrative burden of dealing with insurance companies, which he cites as an astonishing 61 hours per week per physician (presumably spread across a number of staff). Certainly, this seems to be a key issue. But Sorum’s other three points don’t necessarily support a single-payer system. He also argues that the insurance system is leading to increasing deductibles and co-payments placed on patients, limiting access to medications, as drug prices rise. Indeed, Garber and Skinner note also that high deductibles limit the use of highly cost-effective measures and actually have the opposite effect of reducing productive efficiency. A single payer system per se would not solve this, it would need significant subsidies and regulation as well, and as our previous paper shows, other measures can be used to bring down drug prices. Sorum also argues that the US insurance system places an unnecessary burden from quality measures and assessment as well as electronic medical records used to collect information for billing purposes. But these issues of quality and electronic medical records have been discussed in the context of many health care systems, not least the NHS, as the political and regulatory framework still requires this. So a single-payer system is not a solution here. A key difference between the US and elsewhere that Garber and Skinner identify is that the US permits much more heterogeneity in access to and use of health care (e.g. overuse by the wealthy and underuse by the poor). Significant political barriers stand in the way of a single payer system, and since other means can be used to achieve universal coverage, such as the provisions in the Affordable Care Act, maybe internists would be better directing their energy at more achievable goals.

Social ties in academia: a friend is a treasure. Review of Economics and Statistics [RePEcPublished 2nd March 2018

If you ever wondered whether the reason you didn’t get published in that top economics journal was that you didn’t know the right people, you may well be right! This article examines the social ties between authors and editors of the top four economics journals. Almost half of the papers published in these journals had at least one author with a connection to an editor, either through working in the same department, co-authoring a paper, or PhD supervision. The QJE appears to be the worst offender with (if I’ve read this correctly) all authors between 2000 and 2006 getting their PhD in either Harvard or MIT. So don’t bother trying to get published there! This article also shows that you’re more likely to get a paper into the journals when your former PhD supervisor is editing it. Given how much sway a paper published in these journals has on the future careers of young economists, it is disheartening to see the extent of nepotism in the publication process. Of course, one may argue that it just so happens that those that work at the top journals associate most frequently with those who write the best papers. But given even a little understanding of human nature, one would be inclined to discount this explanation. We have all previously asked ourselves, especially when writing a journal round-up, how this or that paper got into a particularly highly regarded journal, now we know…

Credits

Thesis Thursday: Francesco Longo

On the third Thursday of every month, we speak to a recent graduate about their thesis and their studies. This month’s guest is Dr Francesco Longo who has a PhD from the University of York. If you would like to suggest a candidate for an upcoming Thesis Thursday, get in touch.

Title
Essays on hospital performance in England
Supervisor
Luigi Siciliani
Repository link
http://etheses.whiterose.ac.uk/18975/

What do you mean by ‘hospital performance’, and how is it measured?

The concept of performance in the healthcare sector covers a number of dimensions including responsiveness, affordability, accessibility, quality, and efficiency. A PhD does not normally provide enough time to investigate all these aspects and, hence, my thesis mostly focuses on quality and efficiency in the hospital sector. The concept of quality or efficiency of a hospital is also surprisingly broad and, as a consequence, perfect quality and efficiency measures do not exist. For example, mortality and readmissions are good clinical quality measures but the majority of hospital patients do not die and are not readmitted. How well does the hospital treat these patients? Similarly for efficiency: knowing that a hospital is more efficient because it now has lower costs is essential, but how is that hospital actually reducing costs? My thesis tries to answer also these questions by analysing various quality and efficiency indicators. For example, Chapter 3 uses quality measures such as overall and condition-specific mortality, overall readmissions, and patient-reported outcomes for hip replacement. It also uses efficiency indicators such as bed occupancy, cancelled elective operations, and cost indexes. Chapter 4 analyses additional efficiency indicators, such as admissions per bed, the proportion of day cases, and proportion of untouched meals.

You dedicated a lot of effort to comparing specialist and general hospitals. Why is this important?

The first part of my thesis focuses on specialisation, i.e. an organisational form which is supposed to generate greater efficiency, quality, and responsiveness but not necessarily lower costs. Some evidence from the US suggests that orthopaedic and surgical hospitals had 20 percent higher inpatient costs because of, for example, higher staffing levels and better quality of care. In the English NHS, specialist hospitals play an important role because they deliver high proportions of specialised services, commonly low-volume but high-cost treatments for patients with complex and rare conditions. Specialist hospitals, therefore, allow the achievement of a critical mass of clinical expertise to ensure patients receive specialised treatments that produce better health outcomes. More precisely, my thesis focuses on specialist orthopaedic hospitals which, for instance, provide 90% of bone and soft tissue sarcomas surgeries, and 50% of scoliosis treatments. It is therefore important to investigate the financial viability of specialist orthopaedic hospitals relative to general hospitals that undertake similar activities, under the current payment system. The thesis implements weighted least square regressions to compare profit margins between specialist and general hospitals. Specialist orthopaedic hospitals are found to have lower profit margins, which are explained by patient characteristics such as age and severity. This means that, under the current payment system, providers that generally attract more complex patients such as specialist orthopaedic hospitals may be financially disadvantaged.

In what way is your analysis of competition in the NHS distinct from that of previous studies?

The second part of my thesis investigates the effect of competition on quality and efficiency under two different perspectives. First, it explores whether under competitive pressures neighbouring hospitals strategically interact in quality and efficiency, i.e. whether a hospital’s quality and efficiency respond to neighbouring hospitals’ quality and efficiency. Previous studies on English hospitals analyse strategic interactions only in quality and they employ cross-sectional spatial econometric models. Instead, my thesis uses panel spatial econometric models and a cross-sectional IV model in order to make causal statements about the existence of strategic interactions among rival hospitals. Second, the thesis examines the direct effect of hospital competition on efficiency. The previous empirical literature has studied this topic by focusing on two measures of efficiency such as unit costs and length of stay measured at the aggregate level or for a specific procedure (hip and knee replacement). My thesis provides a richer analysis by examining a wider range of efficiency dimensions. It combines a difference-in-difference strategy, commonly used in the literature, with Seemingly Unrelated Regression models to estimate the effect of competition on efficiency and enhance the precision of the estimates. Moreover, the thesis tests whether the effect of competition varies for more or less efficient hospitals using an unconditional quantile regression approach.

Where should researchers turn next to help policymakers understand hospital performance?

Hospitals are complex organisations and the idea of performance within this context is multifaceted. Even when we focus on a single performance dimension such as quality or efficiency, it is difficult to identify a measure that could work as a comprehensive proxy. It is therefore important to decompose as much as possible the analysis by exploring indicators capturing complementary aspects of the performance dimension of interest. This practice is likely to generate findings that are readily interpretable by policymakers. For instance, some results from my thesis suggest that hospital competition improves efficiency by reducing admissions per bed. Such an effect is driven by a reduction in the number of beds rather than an increase in the number of admissions. In addition, competition improves efficiency by pushing hospitals to increase the proportion of day cases. These findings may help to explain why other studies in the literature find that competition decreases length of stay: hospitals may replace elective patients, who occupy hospital beds for one or more nights, with day case patients, who are instead likely to be discharged the same day of admission.

Sam Watson’s journal round-up for 30th October 2017

Every Monday our authors provide a round-up of some of the most recently published peer reviewed articles from the field. We don’t cover everything, or even what’s most important – just a few papers that have interested the author. Visit our Resources page for links to more journals or follow the HealthEconBot. If you’d like to write one of our weekly journal round-ups, get in touch.

Conditional cash transfers: the case of Progresa/OportunidadesJournal of Economic Literature [RePEc] Published September 2017

The Progresa/Oportunidades programme was instigated in Mexico in 1995. The main innovation of the programme was a series of cash payments conditional on various human capital investments in children, such as regular school attendance and health check-ups. Beginning principally in rural areas, it expanded to urban areas in 2000-1. Excitingly for researchers, randomised implementation of the programme was built into its rollout, permitting evaluation of its effectiveness. Given it was the first such programme in a low- or middle-income country to do this, there has been a considerable amount of analysis and literature published on the topic. This article provides an in-depth review of this literature – incorporating over one hundred articles from economics and health journals. I’ll just focus on the health-related aspects of the review rather than education, labour market, or nutrition outcomes, but they’re also worth a look. The article provides a simple theoretical model about the effects of conditional cash transfers to start with and suggests that they have both a price effect, through reducing the shadow wage of time in activities other than those to which the payment is targeted, and an income effect, by increasing total income. The latter effect is ambiguous in its direction. For health, a large number of outcomes including child mortality and height, behavioural problems, obesity, and depression have all been assessed. For the most part  this has been through health modules applied to a subsample of people in surveys, which may limit the conclusions one can make for reasons such as attrition in the samples of treated and control households. Generally, the programme has demonstrated positive health effects (of varying magnitudes) in both the short and medium terms. Health care utilisation increased and with it there was a reduction in self-reported illness, behavioural problems, and obesity. However, positive effects are not reported universally. For example, one study reported an increase in child height in the short term, but in the medium term little change was reported in height-for-age z-scores in another study, which may suggest children catch-up in their growth. Nevertheless, it seems as though the programme succeeded in its aims, although there remains the question of its cost-benefit ratio and whether these ends could have been achieved more cost-effectively by other means. There is also the political question about the paternalism of the programme. While some political issues are covered, such as the perception of the programme as a vehicle for buying votes, and strategies for mitigating these issues, the issue of its acceptability to poor Mexicans is not well covered.

Health‐care quality and information failure: evidence from Nigeria. Health Economics [PubMedPublished 23rd October 2017

When we conceive of health care quality we often think of preventable harm to patients. Higher quality institutions make fewer errors such as incorrect diagnoses, mistakes with medication, or surgical gaffes. However, determining when an error has been made is difficult and quality is often poorly correlated with typical measures of performance like standardised mortality ratios. Evaluating quality is harder still in resource-poor settings where there are no routine data for evaluation and often an absence of patient records. Patients may also have less knowledge about what constitutes quality care. This may provide an environment for low-quality providers to remain in business as patients do not discriminate on the basis of quality. Patient satisfaction is another important aspect of quality, but not necessarily related to more ‘technical’ aspects of quality. For example, a patient may feel that they’ve not had to wait long and been treated respectfully even if they have been, unbeknownst to them, misdiagnosed and given the wrong medication. This article looks at data from Nigeria to examine whether measures of patient satisfaction are correlated with technical quality such as diagnostic accuracy and medicines availability. In brief, they report that there is little variation in patient satisfaction reports, which may be due to some reporting bias, and that diagnostic accuracy was correlated with satisfaction but other markers of quality were not. Importantly though, the measures of technical quality did little to explain the overall variation in patient satisfaction.

State intimate partner violence-related firearm laws and intimate partner homicide rates in the United States, 1991 to 2015. Annals of Internal Medicine [PubMedPublished 17th October 2017

Gun violence in the United States is a major health issue. Other major causes of death and injury attract significant financial investment and policy responses. However, the political nature of firearms in the US limit any such response. Indeed, a 1996 law passed by Congress forbade the CDC “to advocate or promote gun control”, which a succession of CDC directors has interpreted as meaning no federally funded research into gun violence at all. As such, for such a serious cause of death and disability, there is disproportionately little research. This article (not federally funded, of course) examines the impact of gun control legislation on inter-partner violence (IPV). Given the large proportion of inter-partner homicides (IPH) carried out with a gun, persons convicted of IPV felonies and, since 1996, misdemeanours are prohibited from possessing a firearm. However, there is variation in states about whether those convicted of an IPV crime have to surrender a weapon already in their possession. This article examines whether states that enacted ‘relinquishment’ laws that force IPV criminals to surrender their weapons reduced the rate of IPHs. They use state-level panel data and a negative binomial fixed effects model and find that relinquishment laws reduced the risk of IPHs by around 10% and firearm-related IPH by around 15%.

Credits